Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,224 total articles
Tutor Perini's Q2 momentum layered onto a record backlog and strong free cash flow profile makes a compelling risk/reward. Valuation on a cash-flow basis is reasonable, balance sheet is conservative, and index flows alongside continued infrastructure spending support upside to the $100+ level. I recommend a tactical long for swing traders with clea…
Vestas looks positioned to benefit from accelerating global wind installations and a backlog that should convert to revenue across the next 12-18 months. The trade targets a rebound in execution and margin recovery, with a clear entry at $42.00, stop at $36.00 and a $55.00 target over a 180-trading-day horizon.
Veeva combines industry-leading life-sciences cloud software with high-margin recurring revenue and strong free cash flow generation. After beating Q1 estimates and raising FY2027 guidance, the stock looks attractive for a long trade: entry $269.00, stop $240.00, target $320.00, horizon 180 trading days.
Amdocs (DOX) trades like a mature, cash-generative software company on the cusp of secular tailwinds from 5G, cloud-native OSS/BSS adoption and AI-enabled monetization. At roughly $6.7B market cap, a mid-teens P/E and a FCF yield north of 7%, the stock offers a clear value case for a long trade over the next 180 trading days—with defined entry, tar…
The Hartford Sustainable Municipal Bond Fund offers a compelling risk-reward today: attractive current yield exposure to municipal credit with an ESG tilt, plus a meaningful path to capital appreciation if the fund’s discount to NAV narrows as interest rates stabilize and demand for tax-exempt sustainable assets resumes. I recommend a tactical long…
Schaeffler is trading like a company still in free-fall while its underlying business has durable technology exposure to electrification and industrial automation. The valuation is depressed enough to justify taking a long position if management can show measurable margin stabilization and working-capital discipline. This trade lays out an entry at…
AMD has already run hard in 2026, but fundamentals still support a constructive stance. Mix of server CPU share gains, expanding AI accelerator wins and healthy free cash flow justify a medium-risk long trade. Valuation is rich, so position sizing and a clear stop are critical.
SAP has moved off its July lows and is showing constructive technical and fundamental signs that the rebound can continue. With a $259.3B market cap, a PE of 27.1, and rising short interest flows, the stock offers a tactical long opportunity. Execution risk on AI and recurring-revenue conversion remains the main watch item; the trade plan below pri…
Motorcar Parts of America (MPAA) offers an asymmetric mid-term trade: record revenue growth, inexpensive valuation (EV/EBITDA ~6.4, EV/Sales ~0.48) and a near-oversold technical profile around $11.46. I favor a disciplined long with an entry at $11.46, stop at $10.00 and a $15.00 target over the next 45 trading days, sized to limit downside.
Summit Therapeutics (SMMT) has two conflicting narratives: a legacy antibiotic program and a headline-making lung cancer BLA. With the FDA review active for ivonescimab and technicals stabilizing, the stock offers an asymmetric long opportunity. This note upgrades the rating and lays out entry, stop, targets, catalysts and the key risks that would …
Amazon is trading at a rare valuation sweet spot for the combination of scale, cash generation (despite recent FCF noise), and clear capital-allocation optionality. Buy for a long-term position with an entry at $259, a stop at $246 and a primary target of $300 within 180 trading days while watching AWS traction and cash-flow normalization.
Nebius (NBIS) is an AI-specialist cloud operator scaling into hyperscaler contracts, posting hyper-growth and improving unit economics. At a $58.2B market cap and a stretched multiple today, the stock looks like a long-term growth trade for investors willing to accept near-term volatility. Entry at $214.04, stop at $170.00 and a primary target of $…
Advanced Micro Devices sits squarely in the center of the next AI wave: expanding server-CPU traction, new high-memory accelerators, and large cloud partnerships. The market already prices a lot of that optimism (market cap ~$785B, P/E ~123), but we think a clear execution run through late 2026 into 2027 offers an actionable long-term trade. Entry …
CoreWeave sits at the center of the AI compute boom: enormous revenue growth and GPU pricing power, but a capital structure that forces volatile outcomes. This trade idea targets idiosyncratic upside if utilization and pricing stabilize, while keeping a tight stop to limit downside from debt-driven funding shocks.
Kohl's is trading like a broken retailer while still generating meaningful free cash flow and trading at single-digit multiples. This trade targets a rebound back toward mid-cycle valuation as comps stabilize and short-covering pressure eases. Entry at $18.02, stop at $15.50, target $24.00 over a 180 trading day horizon.
SoftBank Group offers a concentrated, diversified exposure to the global AI investment wave through its Vision Funds, chip/IP holdings, and public stakes. The stock trades like a holding company with a persistent discount to underlying asset value — a structural opportunity if management can execute on monetization and capital returns. This trade s…
Kura Oncology's approved menin inhibitor KOMZIFTI has earned NCCN recognition and a Japanese registrational program. Clinical expansion of ziftomenib into combination regimens and positive combo data from other Kura programs suggest upside to revenue and multiple expansion. Given the momentum and reasonable valuation for a clinical-stage commercial…
PagSeguro (PAGS) is trading near $9.07 after reports that the founder has stepped down while retaining control. The company's payment-acquiring, POS and digital-account franchise continues to generate cash and low-multiple earnings. Given a market cap of roughly $2.52B, a PE ~6.3 and PB ~0.86, I favor a long trade sized modestly for patients willin…
Rocket Lab's valuation is anchored to Neutron, but the business has already scaled into larger, recurring revenue streams: record backlog (~$2.36B), a $397M Space Force contract, healthy Electron cadence and growing Space Systems revenue. This trade idea buys that structural growth while respecting high execution risk and a still-rich valuation.
Ironwood (IRWD) is inexpensive on headline multiples and backed by strong cash generation and bullish 2026 LINZESS guidance, but the stock is binary: a successful confirmatory Phase 3 path for apraglutide would re-rate the shares while a negative outcome or regulatory delay would likely drive a steep sell-off. This trade idea lays out a defined lon…
Cleveland-Cliffs (CLF) trades like a levered call on North American steel prices. The stock is cheap on price-to-sales and book value, but the company's integrated blast-furnace footprint, heavy leverage and volatile contracts make equity outcomes binary. This trade gives you directional exposure to a steel-price rally while limiting downside with …
Melrose's announcement around the Garden Grove asset removes a key overhang and should give the stock some breathing room. That said, execution on integration, cash conversion and debt reduction remains the dominant driver for returns. This trade idea sizes a tactical long with clearly defined entry, stop and target framed around the remaining exec…
Harmonic reported a clear operational inflection: two consecutive beats and raised guidance, yet the stock barely budged. The setup favors a mid-term long trade into re-rating catalysts — product traction in broadband and cloud video, improving cash flow, and relatively modest leverage — balanced against execution, legal, and competitive risks.
EQT offers a long-term buy opportunity driven by durable demand for U.S. natural gas, a clean balance sheet, and attractive valuation metrics. With a market cap near $34.5B, a P/E around 12.5 and free cash flow of roughly $3.76B, the stock provides a disciplined way to play secular tailwinds like LNG exports, data center gas demand, and infrastruct…
Royalty Pharma (RPRX) has continued to execute: steady cash generation, a $500M funding deal with Teva, new hires to expand in Asia, and a quarterly dividend. The balance sheet and free cash flow ($2.98B) underpin a re-rating opportunity as the market rewards recurring royalty cash flows and growth from development-stage deals. We outline a swing t…
